PATENT CLAIM ANALYSIS

Application Number: 16013795
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["530", "323000"]

Abstract:
The invention describes peptide ligands specific for human plasma Kallikrein.

Claim (Index 14):
The method of  claim 13 , wherein the ophthalmic disorder is diabetic macular oedema.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 94.0
- Lexical Diversity: 1.0
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14781294', '14350263', '15029248', '14849637', '14339327']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7405799170603329
- 35 USC 102 Novelty (BERT): 0.5594086478950093
- Combined Prediction Score: 0.7224627901438005
- Mean Citation Score: 387.978304
- Max Citation Score: 657.2139
- Similarity Product: 308.0312724384873

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test